Search

Your search keyword '"Barnes, John"' showing total 5 results
Start Over Author "Barnes, John" Topic antiviral agents Publication Year Range Last 50 years Publisher centers for disease control & prevention (cdc)
5 results on '"Barnes, John"'

1. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1.

Author

Mishin, Vasiliy P., Patel, Mira C., Chesnokov, Anton, De La Cruz, Juan, Ha T. Nguyen, Lollis, Lori, Hodges, Erin, Yunho Jang, Barnes, John, Uyeki, Timothy, Davis, Charles T., Wentworth, David E., Gubareva, Larisa V., Nguyen, Ha T, and Jang, Yunho

Subjects
ANIMAL experimentation, ANTIVIRAL agents, AVIAN influenza, CELL lines, COMPARATIVE studies, DOGS, HETEROCYCLIC compounds, INFLUENZA, RESEARCH methodology, MEDICAL cooperation, MICROBIAL sensitivity tests, ORTHOMYXOVIRUSES, POULTRY, PYRIDINE, RESEARCH, SULFUR compounds, SWINE, EVALUATION research, INFLUENZA A virus, INFLUENZAVIRUS C, INFLUENZA B virus, ORTHOMYXOVIRUS infections, PHARMACODYNAMICS
Abstract

Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2-98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses of avian and swine origin, including viruses that have pandemic potential and those resistant to neuraminidase inhibitors. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

2. Update: Influenza Activity -- United States, October 4-November 28, 2015.

Author

Smith, Sophie, Blanton, Lenee, Kniss, Krista, Mustaquim, Desiree, Steffens, Craig, Reed, Carrie, Bramley, Anna, Flannery, Brendan, Fry, Alicia M., Grohskopf, Lisa A., Bresee, Joseph, Wallis, Teresa, Garten, Rebecca, Xiyan Xu, Abd Elal, Anwar Isa, Gubareva, Larisa, Barnes, John, Wentworth, David E., Burns, Erin, and Katz, Jacqueline

Subjects
INFLUENZA, PUBLIC health, PNEUMONIA, ANTIVIRAL agents, DRUG resistance in microorganisms, PATHOLOGICAL laboratories
Abstract

The article discusses overall influenza activity in the U.S. between October 4 and November 28, 2015. Topics include pneumonia- and influenza-associated morbidity, geographic spread of influenza activity, antiviral resistance of influenza viruses, and percentage of respiratory specimens testing positive for influenza reported by clinical laboratories.

Published
2015
Full Text
View/download PDF

3. R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses.

Author

Sleeman, Katrina, Guo, Zhu, Barnes, John, Shaw, Michael, Stevens, James, and Gubareva, Larisa V.

Subjects
NEURAMINIDASE, ANTIVIRAL agents, VIRUS inhibitors, AVIAN influenza A virus, INFLUENZA A virus, AVIAN influenza treatment
Abstract

Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

4. Update: Influenza Activity -- United States, September 30, 2018--February 2, 2019.

Author

Blanton, Lenee, Dugan, Vivien G., Elal, Anwar Isa Abd, Alabi, Noreen, Barnes, John, Brammer, Lynnette, Budd, Alicia P., Burns, Erin, Cummings, Charisse N., Garg, Shikha, Garten, Rebecca, Gubareva, Larisa, Kniss, Krista, Kramer, Natalie, O'Halloran, Alissa, Reed, Carrie, Rolfes, Melissa, Sessions, Wendy, Taylor, Calli, and Xu, Xiyan

Subjects
INFLUENZA diagnosis, INFLUENZA prevention, INFLUENZA transmission, ANTIVIRAL agents, INFLUENZA epidemiology, VIRAL pneumonia, DISEASE susceptibility, DRUG resistance in microorganisms, HOSPITAL care, OUTPATIENT services in hospitals, INFLUENZA, INFLUENZA vaccines, INFLUENZA A virus, H3N2 subtype, POPULATION geography, PUBLIC health surveillance, INFLUENZA B virus, DISEASE risk factors
Abstract

The article presents an influenza activity update in the U.S. from September 30, 2018-February 2, 2019. Topics discussed include the virologic surveillance for influenza, the antigenic and genetic qualities, and antiviral susceptibility of influenza viruses, outpatient illness monitoring, and the geographic scope of influenza activity. Also noted are estimates on the numbers of symptomatic illnesses, medical visits, hospitalizations, and deaths caused by influenza virus infection.

Published
2019

5. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1.

Author

Mishin, Vasiliy P., Patel, Mira C., Chesnokov, Anton, De La Cruz, Juan, Ha T. Nguyen, Lollis, Lori, Hodges, Erin, Yunho Jang, Barnes, John, Uyeki, Timothy, Davis, Charles T., Wentworth, David E., Gubareva, Larisa V., Nguyen, Ha T, and Jang, Yunho

Subjects
*ANIMAL experimentation, *ANTIVIRAL agents, *AVIAN influenza, *CELL lines, *COMPARATIVE studies, *DOGS, *HETEROCYCLIC compounds, *INFLUENZA, *RESEARCH methodology, *MEDICAL cooperation, *MICROBIAL sensitivity tests, *ORTHOMYXOVIRUSES, *POULTRY, *PYRIDINE, *RESEARCH, *SULFUR compounds, *SWINE, *EVALUATION research, *INFLUENZA A virus, *INFLUENZAVIRUS C, *INFLUENZA B virus, *ORTHOMYXOVIRUS infections, *PHARMACODYNAMICS
Abstract

Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2-98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses of avian and swine origin, including viruses that have pandemic potential and those resistant to neuraminidase inhibitors. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results